EGFRvIII as a promising target for antibody-based brain tumor therapy (Q34157678)

31 July 2017

1 reference

title

EGFRvIII as a promising target for antibody-based brain tumor therapy (English)

1 reference

31 July 2017

1 reference

1 reference

3

Bigner DD

1 reference

31 July 2017

Kuan CT

1

1 reference

PubMed ID

11210174

31 July 2017

Wikstrand CJ

series ordinal

2

1 reference

31 July 2017

1 January 2000

1 reference

31 July 2017

Brain Tumor Pathology

1 reference

31 July 2017

17

1 reference

31 July 2017

2

1 reference

31 July 2017

71-78

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02482738

31 July 2017

0 references

cites work

A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors

1 reference

https://api.crossref.org/works/10.1007%2FBF02482738

Crossref

reference URL

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02482738

Crossref

reference URL

In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02482738

Crossref

reference URL

21 January 2018

Identifiers

DOI

10.1007/BF02482738

1 reference

31 July 2017

1 reference

PubMed ID

11210174